Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
HOME > ACADEMIA
ACADEMIA
- Patients Need to Be Warned of Risk of Relapse if They Discontinue Antidepressants: Prof. Iwata
October 6, 2011
- Med. Institutions Prefer GE Anticancer Drugs from Companies with Better Support Systems: Ms Matsui of NCC Hospital East
October 3, 2011
- Decision to Prescribe Prazaxa Should Be Left to Specialists for Now: JCS Press Seminar
September 30, 2011
- 95% of Patients Favor Comprehensive Agreements to Use Tissue for Research: NCC
September 26, 2011
- JASSO to Announce New Diagnostic Guidelines for Obesity
September 26, 2011
- Insurers Favor Incentives to Pharmacies to Promote Use of Generics: Seminar
September 26, 2011
- Regulatory Science Society Holds 1st Scientific Convention
September 19, 2011
- NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
- Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
- 42 Nat’l Univ. Hospitals Share Drug Price Information to Reduce Purchase Costs
September 12, 2011
- NCC Aims to Become World’s Leading Early Clinical Development Center
September 12, 2011
- Intensive Therapy with Rosuvastatin Effective at Inhibiting Progression of IMT: JART Study
September 12, 2011
- Apixaban Superior to Warfarin, Risk of Major Bleeding Down 30%: ESC
September 12, 2011
- ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
- JCS Recommends Dabigatran in Patients with CHADS2 Score of 1
September 5, 2011
- Osaka Univ. Hospital to Lead Innovation to Discover Globally Competitive Drugs
September 5, 2011
- Univ. of Tokyo Hospital to Initiate PI Trial of Radical AD Treatments
September 5, 2011
- Keio Univ. to Begin PI Trials of New Drugs for Refractory Immunological Diseases in FY2012
September 5, 2011
- Generic Drugs Accounted for 23.1% of Drug Sales Volume in April-June: JGA
September 2, 2011
- National Cancer Center to Set Up Phase I Center by End of FY2011
September 1, 2011
ページ
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…